Respiri Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Respiri.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:RSH - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1	-7	-7	-7	N/A
3/31/2024	1	-7	-6	-6	N/A
12/31/2023	1	-6	-5	-5	N/A
9/30/2023	1	-6	-5	-5	N/A
6/30/2023	1	-6	-5	-4	N/A
3/31/2023	1	-6	-6	-6	N/A
12/31/2022	1	-6	-8	-8	N/A
9/30/2022	1	-6	-8	-8	N/A
6/30/2022	1	-7	-8	-8	N/A
3/31/2022	1	-7	-7	-7	N/A
12/31/2021	1	-8	-6	-6	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-11	-7	-7	N/A
3/31/2021	1	-12	-7	-7	N/A
12/31/2020	1	-12	-7	-7	N/A
9/30/2020	2	-10	-6	-6	N/A
6/30/2020	2	-7	-5	-5	N/A
3/31/2020	2	-7	-5	-5	N/A
12/31/2019	2	-7	-6	-6	N/A
9/30/2019	2	-8	-6	-6	N/A
6/30/2019	1	-8	-6	-6	N/A
3/31/2019	1	-7	-5	-5	N/A
12/31/2018	1	-6	-4	-4	N/A
9/30/2018	1	-4	-3	-3	N/A
6/30/2018	1	-3	-2	-2	N/A
3/31/2018	1	-2	N/A	-2	N/A
12/31/2017	2	-1	N/A	-2	N/A
9/30/2017	1	-2	N/A	-2	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-4	N/A	-3	N/A
6/30/2016	1	-4	N/A	-2	N/A
3/31/2016	0	-5	N/A	-3	N/A
12/31/2015	0	-5	N/A	-4	N/A
9/30/2015	0	-5	N/A	-5	N/A
6/30/2015	0	-5	N/A	-6	N/A
3/31/2015	0	-6	N/A	-6	N/A
12/31/2014	0	-6	N/A	-7	N/A
9/30/2014	0	-8	N/A	-8	N/A
6/30/2014	0	-10	N/A	-9	N/A
3/31/2014	0	-10	N/A	-8	N/A
12/31/2013	0	-10	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RSH's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if RSH's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if RSH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if RSH's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if RSH's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RSH's Return on Equity is forecast to be high in 3 years time

Respiri Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Respiri Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.007 loss in FY 2023)

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.6 million.

Respiri Limited Announces Executive Changes

New major risk - Share price stability

Respiri Limited has completed a Follow-on Equity Offering in the amount of AUD 1.3876 million.

Respiri Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.

Less than half of directors are independent

Respiri Limited's (ASX:RSH) CEO Will Probably Find It Hard To See A Huge Raise This Year

Respiri Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.009 loss in FY 2022)

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

New minor risk - Share price stability

Respiri Limited Appoints Brian Leedman as Non-Executive Director

First half 2023 earnings released: AU$0.003 loss per share (vs AU$0.004 loss in 1H 2022)

Respiri Limited Announces Arkansas Heart Hospital Commences Patients on Wheezo RPM

Respiri Limited Announces Minnesota Lung Center Wheezo Rpm Pilot Program Patient Selection Has Been Finalised and Patient Onboarding Has Successfully Commence

No independent directors

Respiri Announces First Patients Enrolled into Wheezo® Remote Patient Monitoring Programs, Further Validating USA Business Model

Respiri Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings released

We're Keeping An Eye On Respiri's (ASX:RSH) Cash Burn Rate

Respiri Limited Announces Executive Changes

Respiri Limited Announces New £2 Million NIHR-Funded UK Paediatric Asthma Clinical Trial with wheezo

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Respiri Limited Appoints Brad Snow as A Non-Executive Director

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Respiri Limited Announces Resignation of Director of Dr. Thomas Duthy

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Full year 2021 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in FY 2020)

Respiri Limited Announces Wheezo Registered and Approved for Sale in the UK Market

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

Insider recently bought AU$95k worth of stock

Respiri (ASX:RSH) Is In A Good Position To Deliver On Growth Plans

Respiri Limited Announces New Partnership with Pharmacy 4 Less Banner Group

Respiri Limited Holds Media Events to Mark the Launch of Wheezo

Respiri Limited, Annual General Meeting, Dec 16, 2020

Respiri Limited Files Additional Patent Application

Respiri Limited Announces A Partnership with Entech Electronics for the Global Supply of the Ground Breaking Wheezo

Respiri Limited to Report Fiscal Year 2020 Results on Aug 25, 2020

Respiri Limited announced that it expects to receive AUD 0.09 million in funding

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies